Introduction

M
ultimorbidity is commonly understood to be the coexistence of multiple health conditions in an individual. 1, 2 A related term, comorbidity, describes the burden of illness co-existing with a particular disease of interest. 3 Multimorbidity is a growing global public health challenge as populations age and the prevalence of long-term conditions rises. 1, 2 Multimorbidity is associated with poorer outcomes and the increased use of health and social care services with associated costs. 4, 5 There is increasing awareness that healthcare services are not adequately designed to meet the challenges of multimorbidity. Secondary care services are generally single disease focussed. 6, 7 Practitioners, particularly in primary care, face challenges in using clinical guidelines that are generally developed for single conditions or groups of similar conditions. 8 These issues bring associated risks, for example, polypharmacy, 8, 9 and challenges associated with managing patients with complex needs in resource limited environments. 6 Multimorbidity also places a burden on individuals who face poorer quality of life and increased disability. 10 It is highly correlated with frailty (an age-related decline leading to reduced reserves of physical and mental health capacity, resulting in vulnerability to stressors and an increased risk of poor health outcomes). 11, 12 Despite these challenges, there is no international consensus regarding the best way to define and measure multimorbidity. 13 This makes carrying out and interpreting research, comparing findings across populations and developing guidelines and interventions difficult. A review of prevalence studies of multimorbidity found estimates ranging from between less than 5% to more than 95%, often due to differences in the operational definition of multimorbidity. 2 The National Institute for Health and Care Excellence (NICE) recently developed a multimorbidity guideline and commented that measuring the prevalence of multimorbidity is complex due to the varying measures being used. 14 A number of reviews have summarized the multimorbidity definitions or measures used in primary studies. Our aim was to build consensus on the most appropriate ways to define and measure multimorbidity by pooling the findings of these systematic reviews.
Methods
The PRISMA 2009 checklist guided method development and reporting of findings. 15 Medline, Embase, PubMed and the Cochrane database of systematic reviews were searched from database inception to 13 February 2017. The search strategy was comparable across all databases. At the time of searching, there was no MeSH term for multimorbidity. The search terms relating to 'multimorbidity' and its measures were drawn from a previous systematic review of the multimorbidity literature. 16 These were combined by the Boolean operator 'AND' with 'review' as a title word. The terms were searched in the title only, as an initial trial search found that widening this to the abstract or full text significantly reduced the ability to detect relevant reviews. The search strategy is in Supplementary table S1.
Systematic reviews of the multimorbidity literature which examined multimorbidity definitions and/or measures as a central focus of the review were included. While comorbidity is now commonly accepted to be distinct from multimorbidity, it is known that the terms have been used synonymously in the past. Reviews of comorbidity where no specific index disease was considered were therefore eligible. Systematic reviews that did not have the primary aim to summarize multimorbidity definitions and measures were excluded. Reviews that were 'narrative' or 'semistructured' or which otherwise were not systematic reviews were excluded.
Title, abstract and full-text screening were carried out independently by two authors (MCJ and SWM). Disagreement was resolved by CB. Primary data extraction was carried out by MCJ with four others acting as independent second reviewers (CB, MC, GJP and SWM). The data extraction form was prepared and piloted by MCJ and finalized by discussion with the other reviewers. Data extraction included the review characteristics, the definition and measures of multimorbidity presented in the review and the rationale behind any recommended measures of multimorbidity (if given). Scottish Intercollegiate Guidelines Network critical appraisal checklists 17 were used to assess the quality of included reviews ('low quality', 'acceptable' or 'high quality'). The results were combined narratively. Figure 1 summarizes the results of the search. Out of 1051 articles sourced during the search, there were 432 duplicates. Following screening of titles, abstracts and full texts, six reviews were included. 16, [18] [19] [20] [21] [22] The characteristics of these reviews, including their stated aims, are presented in table 1. The Le Reste and Willadsen reviews focused on the definition of multimorbidity, while the remaining four focussed on measures. The number of studies included by the reviews ranged from 39 to 194. Five reviews were of 'acceptable quality'. 16, [19] [20] [21] [22] De Groot was 'low quality' as they did not report the literature search strategy, the results of the literature search and the identification of papers clearly. 18 
Results
Definitions
The multimorbidity definitions used in the included reviews are in table 2. As described earlier, Le Reste and Willadsen were the only papers focused on reviewing definitions 20, 22 and so the definitions provided by the other four were the authors own.
Le Reste produced a new multimorbidity definition as a result of their review:
''. . . any combination of chronic disease with at least one other disease (acute or chronic) or biopsychosocial factor (associated or not) or somatic risk factor''. 20 Willadsen found that more than a third of studies used a cut-off of two or more conditions to define multimorbidity, another third did not specify any cut-off and the remainder had varying cut-off points. The authors found that less than a third of their included studies used an existing definition of multimorbidity. Additionally, definitions varied according to whether or not they specified a duration of condition (e.g. 'occurrence in the last 5 years' or having lasted 'for at least 3 months') and whether or not they specified the severity of the condition (e.g. staging of the disease). The authors state that consideration of whether included diseases clustered together was considered in only 'a few' articles and there was little consideration of complications of diseases. The authors concluded that the majority of existing definitions are 'more usable for epidemiologists than for clinicians and patients' and recommended the Le Reste definition due to its comprehensive nature for including more than just disease. 22 In the remaining reviews, De Groot and Yurkovich primarily used the term 'comorbidity'. 18, 21 The consensus amongst all four was that multimorbidity is the occurrence of multiple diseases or conditions. Diederichs specified that multimorbidity is two or more chronic conditions. 19 
Measures
Commonly used measures
Le Reste did not focus on multimorbidity measures. 20 The measures covered by the remaining five reviews are in table 3. While the stated aim of Willadsen was to 'explore how multimorbidity is defined in the scientific literature', there was overlap between definitions and measures. 22 The measures included by reviews encompassed disease counts and weighted indices such as the Charlson Index, the Cumulative Illness Rating Scale (CIRS), the Index of Coexistent Disease (ICED), the Adjusted Clinical Groups (ACG) System and the Duke Severity of Illness.
Yurkovich and Huntley examined the frequency of measures. Yurkovich categorized measures as 'administrative data' (the most common being Charlson) and 'medication-based' (the most common being the Chronic Disease Score). 21 Huntley categorized the most common measures as: disease counts, the Charlson index and variations, the ACG system, the CIRS and the Duke Severity Illness Check-list System. 16 Despite the name, disease counts included more than just diseases (e.g. they included categories of conditions). The authors found disease counts being used in 98 studies and the number of disease 'items' included within counts ranged from 9 to 35. 16 Willadsen found that measures included by their papers contained conditions ranging in number from 4 to 147. 22 
Recommended measures
Yurkovich found that diagnosis-based measures such as the Elixhauser index and the Romano adaptation of the Charlson index were best able to predict mortality outcomes while the medication-based Chronic Disease Score was best able to predict health care use. 21 Huntley recommended that researchers select a measure for a study based upon the measure validated for use in that scenario, for example, the Charlson index for predicting mortality. The authors also state that simple counts of diseases or medications perform almost as effectively as complex measures in predicting most outcomes. 16 De Groot assessed the content, criterion and construct validity of measures. They concluded that the Charlson, CIRS, ICED and Kaplan indices are valid and reliable methods for use in clinical research but that other measures (such as disease counts) were more difficult to assess due to limited data. 18 Willadsen did not recommend a single measure and instead, as described previously, stated the importance of including risk factors, symptoms and severity of diseases. 22 Diederichs also did not recommend a single measure. They found studies of disease 20 Review of evidence 'Multimorbidity is defined as any combination of chronic disease with at least one other disease (acute or chronic) or biopsychosocial factor (associated or not) or somatic risk factor. Any biopsychosocial factor, any somatic risk factor, the social network, the burden of diseases, the health care consumption, and the patient's coping strategies may function as modifiers (of the effects of multimorbidity). Multimorbidity may modify the health outcomes and lead to an increased disability or a decreased quality of life or frailty.' Yurkovich et al. 21 
a priori
This review used the definition of comorbidity: 'Comorbidity may be defined as the total burden of illnesses unrelated to the principal diagnosis' Willadsen et al. a: a priori indicates this is the reviewers own definition. counts often did not specify the criteria for the selection of diseases, but if criteria were given these were: high prevalence of the disease, using other indices as a reference point for the selection of disease, or high impact conditions in terms of increased mortality risk, an impact on function and health and the need for management. They recommended 11 conditions selected on the basis of being the most common causes of inpatient and outpatient attendance as well as death in people aged over 64 in Germany. The conditions included cancer, depression, myocardial infarction and hypertension. 19 
Data sources
All five reviews found patient self-report, physician reports, clinical examinations, medical record reviews and administrative data ('coded databases' or 'routine data') were common sources of multimorbidity data among their included studies. 16, 18, 19, 21, 22 No review studied whether any source was superior, although Yurkovich found evidence that the Charlson index derived from self-report and that derived from administrative data had similar abilities to 'predict various outcomes'. 21 De Groot stated that medical chart reviews are preferable for use in smaller studies as they likely yield the most complete data but that this is likely impractical in larger studies and so administrative databases can be used. 18 Similarly, Huntley noted that administrative data have the advantage of ease of use but may be limited by data quality issues. 16 
Discussion
Summary of findings
Our review pooled the findings of six systematic reviews. We found heterogeneity of multimorbidity definitions and measures, but there were a number of commonalities.
Most reviews defined multimorbidity as the occurrence of multiple diseases or conditions, the most common cut-off being two or more. Le Reste produced a new definition that encompassed biopsychosocial factors and somatic risk factors along with disease. 20 This was recommended by Willadsen as being the most clinically relevant definition of multimorbidity available. 22 Common measures included the Charlson, CIRS, ICED, Kaplan, the ACG system and disease counts, with advice that measures be selected based upon the purpose of a particular study. 16, 18 No reviews made recommendations about the most appropriate data sources to use when measuring multimorbidity.
Strengths and limitations
Our systematic review provides a high-level summary of both the definition and measurement of multimorbidity in relevant systematic reviews. Ours is the first to focus upon those reviews which primarily aimed to examine multimorbidity definitions or measures. This is important given the heterogeneity in definitions and measures available and the associated complexity in developing consensus. We acknowledge that reviews such as that by Fortin et al.
(of prevalence studies of multimorbidity) 2 and Marengoni et al. 5 (of ageing and multimorbidity) discuss recommended definitions and measures at the end of their reviews, but we have not included these as their primary aim did not meet our inclusion criteria.
A limitation is that search terms were limited to the title only for practical reasons which means some relevant reviews could be missed. We conducted a test search including these terms in the abstract or full text which revealed no additional reviews in the first 100 titles screened. Additionally, as recommended by PRISMA, systematic reviews should be identified as such in the title. 15 One of the included reviews (examining measures of multimorbidity) was classed as low quality. However, as there were three other reviews examining multimorbidity measures this should reduce the likelihood that this affected our findings.
Comparison with literature
Our findings are consistent with other systematic reviewers who have encountered challenges due to the lack of a common approach towards measuring and defining multimorbidity.
2,23-25
Definitions
Willadsen highlighted that many definitions and measures seem to be tailored towards use in research rather than being clinically relevant. 22 It is true that traditional approaches, for example, measuring multimorbidity using the Charlson or disease counts, do not capture the holistic experience of multimorbidity. For example, we know that an individuals' ability to cope with disease is influenced by both person factors and wider socio-environmental factors and that at a population level, multimorbidity is associated with higher levels of deprivation. 4, [26] [27] [28] [29] [30] The definition by Le Reste is more likely to capture this complexity but the multi-faceted nature of the definition makes it difficult to operationalize in practice. Instead of adding further elements to the definition and measurement of multimorbidity, it is perhaps more appropriate to ensure there is consideration of its holistic nature when studying its determinants and outcomes and when managing it clinically. This would include understanding its relationship with health inequalities in areas of high deprivation, as well as to frailty and the ageing process.
11,12
The cut-off point regarding the minimum number of conditions to equate to being multimorbid needs further consideration. The most common cut-off point found by our reviews was two or more conditions and this was consistent with the findings of Fortin in their review of prevalence studies of multimorbidity. 2 The prevalence of multimorbidity is inevitably affected by the cutoff selected and additionally it is likely that a higher cut-off would select a patient group with a higher burden of multimorbidity. 2 This needs further research, for example, by testing the number of conditions which best identify patients at higher risk of outcomes such as hospital stay, disability, frailty or mortality.
Measures
When multimorbidity is defined and measured on the basis of a count of conditions the measurement of multimorbidity is closely linked to the definition. We have used the term 'disease counts' as this is the common phrase used in the literature, but acknowledge these measures can include a wider spectrum of health conditions (e.g. risk factors for disease). Disease counts are likely more appropriate for scenarios where multiple outcomes are being considered or in which no single weighted measure has been validated. 16 They may also be a more intuitive summary of multimorbidity burden in patients, for example, when showing the link between multimorbidity and socioeconomic status. 4 Additionally, reviews have found that multimorbidity may be more appropriately considered as different common clusters of conditions and this is easier to measure using counts. 24, 31 If researchers are selecting conditions to include in a count the purpose of the work being conducted must be considered. Some conditions, for example, depression, may have greater impact upon patients in terms of quality of life or function. 32 Other conditions such as heart disease may impact more upon health services in terms of number of admissions or treatment costs. 2, 19 In studies using weighted measures the definition and measurement of multimorbidity are more distinct. Many weighted measures were originally developed as comorbidity measures but are increasingly being used as multimorbidity measures. 18 Weighted measures, if used for appropriate outcomes, can assist in predicting patient outcome and future healthcare usage and can also provide an assessment of the burden of multimorbidity experienced by the patient, their carers or health and social care services. 33 Therefore, where the aim is to examine outcomes in patients and to account for the presence of multiple conditions, a validated weighted measure may be more appropriate or informative than a disease count.
Data sources
No review recommended a particular data source to measure multimorbidity. In the wider literature, a number of studies and reviews have compared data sources for comorbidity and multimorbidity measures, often with conflicting findings. 3, 34 The availability of data and the resource implications will additionally affect the choice of data used. For example, while case-note review is viewed as being more complete than administrative data as it is more resource intensive. 3, 34 Another important data source is patient selfreport, which may be more likely to capture conditions which may not be seen as important clinically but impact on function or quality of life. 32 Regardless of measure, different data sources will affect the prevalence of multimorbidity.
2,35
Implications for research and practice Our key recommendation is that researchers be explicit about the definitions and measure(s) they are using and give a rationale for their choice. This will enable comparison of findings across different settings and outcomes as well as progress the evidence base regarding the most appropriate definitions and measures for particular scenarios.
Multimorbidity is an important public health challenge, which is influenced strongly by wider social and environmental factors. In this review, the paper by Le Reste highlighted the holistic nature of multimorbidity. 20 In clinical and public health practice, holistic approaches that take into account more than just the medical management of disease could assist with reducing its impact. However, there is a need for more evidence on the effectiveness of primary care and community-based interventions, including those tackling the challenges experienced by individuals with socioeconomic deprivation. 36 Despite this, recent research in primary care in deprived areas has shown that a co-development model of intervention development for multimorbidity (CARE Plus) was feasible and may be cost-effective, thus pointing to future directions in reducing the burden of multimorbidity. 37, 38 Overall, a definition of multiple co-existing conditions is reasonable and a cut-off should be explicitly defined. Researchers would be consistent with others using a cut-off of two or more. Using a weighted measure validated for the outcome being considered is advised, but where evidence is weak or where multiple outcomes or populations are being considered, the use of disease counts is appropriate. There is precedence for the inclusion of conditions other than solely chronic disease in a multimorbidity measure but a rationale for included and excluded conditions should be given.
Supplementary data
Supplementary data are available at EURPUB online. 
Key points
To improve consensus in defining and measuring multimorbidity, we recommend researchers and practitioners be explicit about the definitions and measure(s) they are using and give a rationale for their choice. We conclude that multimorbidity is the coexistence of multiple conditions (most commonly defined as two or more conditions). Validated multimorbidity measures for particular scenarios should be chosen if these exist. Where there is no validated measure or where multiple outcomes or populations are being considered, disease counts are appropriate.
